Andere Sprachen Luye Pharma Group Ltd.

Aktien

A116Z9

BMG570071099

2186

Verzögert Hong Kong S.E. Andere Börsenplätze 07:56:34 03.05.2024			% 5 Tage	% 1. Jan.
3 ^HKD	-0,66 %		+13,21 %	-19,57 %

27.03.	Luye Pharma Group Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
07.03.	Luye Pharma Group gibt die Markteinführung ihres innovativen Medikaments Zepzelca® (Lurbinectedin) zur Behandlung von SCLC sowohl in Hongkong als auch in Macao bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	07.03.
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	04.03.
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	04.03.
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02.02.
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	01.02.
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	13.12.
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	13.12.
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12.12.
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12.12.
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12.12.
Luye Pharma Group Ltd. Announces Board Changes	06.12.
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05.12.
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	04.12.
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	04.12.
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	01.11.
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	01.11.
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31.10.23
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	09.10.23
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Luye Pharma Group Ltd.

Aktien

A116Z9

BMG570071099

2186

Andere Sprachen

Filter